Hallvard Holdaas

  • Consultant; MD, PhD
 

Publications 2019

Haugen AJ, Langberg NE, Dahle DO, Pihlstrøm H, Birkeland KI, Reisaeter A, Midtvedt K, Hartmann A, Holdaas H, Mjøen G (2019)
Long-term risk for kidney donors with hypertension at donation - a retrospective cohort study
Transpl Int, 32 (9), 960-964
DOI 10.1111/tri.13443, PubMed 30983060

Holdaas H (2019)
People in Transplantation
Transplantation, 103 (8), 1529-1531
DOI 10.1097/TP.0000000000002658, PubMed 31348435

Ju A, Josephson MA, Butt Z, Jowsey-Gregoire S, Tan J, Taylor Q, Fowler K, Dobbels F, Caskey F, Jha V, Locke J, Knoll G, Ahn C, Hanson CS, Sautenet B, Manera K, Craig JC, Howell M, Rutherford C, Tong A, Harden P, Hawley C, Holdaas H, Israni A, Jesse M et al. (2019)
Establishing a Core Outcome Measure for Life Participation: A Standardized Outcomes in Nephrology-kidney Transplantation Consensus Workshop Report
Transplantation, 103 (6), 1199-1205
DOI 10.1097/TP.0000000000002476, PubMed 30300284

Klaasen RA, Egeland EJ, Chan J, Midtvedt K, Svensson M, Bolstad N, Fellström B, Holdaas H, Åsberg A, Bergan S, Vethe NT, Warren DJ (2019)
A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients
Ther Drug Monit, 41 (1), 11-18
DOI 10.1097/FTD.0000000000000580, PubMed 30633722

Mjoen G, Reisæter A, Hartmann A, Dahle DO, Holdaas H (2019)
Regarding age-calibrated glomerular filtration rate
Kidney Int, 95 (1), 234-235
DOI 10.1016/j.kint.2018.10.003, PubMed 30606421

Tunbridge M, Holdaas H, Jardine AG (2019)
Pulse Pressure: A Risk Factor for Renal Transplant Failure or a Useful Therapeutic Target?
Transplantation, 103 (4), 662-663
DOI 10.1097/TP.0000000000002441, PubMed 30188414

Publications 2018

Abedini S, Gøransson L, Cockburn E, Kilany S, Holdaas H (2018)
Immunosuppression Adherence in Stable Kidney Transplant Patients Converted From Immediate- to Prolonged-Release Tacrolimus in Clinical Practice: A Norwegian Study
Transplant Direct, 4 (2), e338
DOI 10.1097/TXD.0000000000000755, PubMed 29464199

Egeland EJ, Reisaeter AV, Robertsen I, Midtvedt K, Strøm EH, Holdaas H, Hartmann A, Åsberg A (2018)
High tacrolimus clearance - a risk factor for development of interstitial fibrosis and tubular atrophy in the transplanted kidney: a retrospective single-center cohort study
Transpl Int, 32 (3), 257-269
DOI 10.1111/tri.13356, PubMed 30252957

García-Carro C, Dörje C, Åsberg A, Midtvedt K, Scott H, Reinholt FP, Holdaas H, Reisaeter AV, Seron D (2018)
Kidney allograft subclinical rejection modulates systemic inflammation measured by C-reactive protein at 1 year after transplantation
Clin Transplant, 32 (3), e13196
DOI 10.1111/ctr.13196, PubMed 29380890

Jardine AG, Hartmann A, Holdaas H (2018)
Long-term renal allograft survival: a quiet revolution
Kidney Int, 94 (5), 853-855
DOI 10.1016/j.kint.2018.08.005, PubMed 30348301

Mafham MM, Staplin N, Emberson J, Haynes R, Herrington W, Reith C, Wanner C, Walker R, Cass A, Levin A, Fellström B, Jiang L, Holdaas H, Kasiske B, Wheeler DC, Landray MJ, Baigent C, SHARP Collaborative Group (2018)
Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection
Nephrol Dial Transplant, 33 (2), 257-264
DOI 10.1093/ndt/gfw396, PubMed 28088776

Mjoen G, Holdaas H (2018)
Mid- and Long-Term Health Risks in Living Kidney Donors
Ann Intern Med, 169 (4), 265
DOI 10.7326/L18-0340, PubMed 30128523

Pedersen HL, Horvei KD, Thiyagarajan D, Norby GE, Seredkina N, Moroni G, Eilertsen GØ, Holdaas H, Strøm EH, Bakland G, Meroni PL, Rekvig OP (2018)
Lupus nephritis: low urinary DNase I levels reflect loss of renal DNase I and may be utilized as a biomarker of disease progression
J Pathol Clin Res, 4 (3), 193-203
DOI 10.1002/cjp2.99, PubMed 29624903

Pihlstrøm HK, Mjøen G, Mucha S, Franke A, Jardine A, Fellström B, Dahle DO, Holdaas H, Melum E (2018)
Genetic markers associated with long-term cardiovascular outcome in kidney transplant recipients
Am J Transplant, 19 (5), 1444-1451
DOI 10.1111/ajt.15191, PubMed 30457209

Solbu MD, Mjøen G, Mark PB, Holdaas H, Fellström B, Schmieder RE, Zannad F, Herrington WG, Jardine AG (2018)
Predictors of atherosclerotic events in patients on haemodialysis: post hoc analyses from the AURORA study
Nephrol Dial Transplant, 33 (1), 102-112
DOI 10.1093/ndt/gfw360, PubMed 27798199

Ussif A, Pihlstrøm H, Pasch A, Holdaas H, Hartmann A, Smerud K, Åsberg A (2018)
Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score
BMC Nephrol, 19 (1), 212
DOI 10.1186/s12882-018-1000-8, PubMed 30134956

Publications 2017

Dahle DO, Grotmol T, Leivestad T, Hartmann A, Midtvedt K, Reisæter AV, Mjøen G, Pihlstrøm HK, Næss H, Holdaas H (2017)
Association Between Pretransplant Cancer and Survival in Kidney Transplant Recipients
Transplantation, 101 (10), 2599-2605
DOI 10.1097/TP.0000000000001659, PubMed 28207636

de Fijter JW, Holdaas H, Øyen O, Sanders JS, Sundar S, Bemelman FJ, Sommerer C, Pascual J, Avihingsanon Y, Pongskul C, Oppenheimer F, Toselli L, Russ G, Wang Z, Lopez P, Kochuparampil J, Cruzado JM, van der Giet M, ELEVATE Study Group (2017)
Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial
Am J Transplant, 17 (7), 1853-1867
DOI 10.1111/ajt.14186, PubMed 28027625

Egeland EJ, Robertsen I, Hermann M, Midtvedt K, Størset E, Gustavsen MT, Reisæter AV, Klaasen R, Bergan S, Holdaas H, Hartmann A, Åsberg A (2017)
High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation
Transplantation, 101 (8), e273-e279
DOI 10.1097/TP.0000000000001796, PubMed 28452920

García-Carro C, Dörje C, Åsberg A, Midtvedt K, Scott H, Reinholt FP, Holdaas H, Seron D, Reisæter AV (2017)
Inflammation in Early Kidney Allograft Surveillance Biopsies With and Without Associated Tubulointerstitial Chronic Damage as a Predictor of Fibrosis Progression and Development of De Novo Donor Specific Antibodies
Transplantation, 101 (6), 1410-1415
DOI 10.1097/TP.0000000000001216, PubMed 27163535

Heldal K, Hartmann A, Lønning K, Leivestad T, Reisæter AV, Line PD, Holdaas H, Midtvedt K (2017)
Should patients older than 65 years be offered a second kidney transplant?
BMC Nephrol, 18 (1), 13
DOI 10.1186/s12882-016-0426-0, PubMed 28077080

Holdaas H, de Fijter JW, Cruzado JM, Massari P, Nashan B, Kanellis J, Witzke O, Gutierrez-Dalmau A, Turkmen A, Wang Z, Lopez P, Bernhardt P, Kochuparampil J, van der Giet M, Murbraech K, ELEVATE Study Group (2017)
Cardiovascular Parameters to 2 years After Kidney Transplantation Following Early Switch to Everolimus Without Calcineurin Inhibitor Therapy: An Analysis of the Randomized ELEVATE Study
Transplantation, 101 (10), 2612-2620
DOI 10.1097/TP.0000000000001739, PubMed 28333860

Holdaas H, Mjøen G, Jardine AG (2017)
Belatacept: Where the BENEFITS Outweigh the Risk
Am J Kidney Dis, 69 (5), 561-563
DOI 10.1053/j.ajkd.2017.02.007, PubMed 28434523

Lindahl JP, Massey RJ, Hartmann A, Aakhus S, Endresen K, Günther A, Midtvedt K, Holdaas H, Leivestad T, Horneland R, Øyen O, Jenssen T (2017)
Cardiac Assessment of Patients With Type 1 Diabetes Median 10 Years After Successful Simultaneous Pancreas and Kidney Transplantation Compared With Living Donor Kidney Transplantation
Transplantation, 101 (6), 1261-1267
DOI 10.1097/TP.0000000000001274, PubMed 27467687

Midtvedt K, Holdaas H, Bergan S, Åsberg A (2017)
Costimulation Blockade: America First, Canada Second … What About Norway?
Am J Transplant, 17 (8), 2230
DOI 10.1111/ajt.14351, PubMed 28508535

Mjøen G, Holdaas H (2017)
Long term risk of mortality after living kidney donation
BMJ, 357, j1770
DOI 10.1136/bmj.j1770, PubMed 28442509

Mjøen G, Holdaas H (2017)
Regarding "Obesity increases the risk of end-stage renal disease among living kidney donors"
Kidney Int, 91 (5), 1256
DOI 10.1016/j.kint.2017.01.034, PubMed 28407879

Norby GE, Mjøen G, Bjørneklett R, Vikse BE, Holdaas H, Svarstad E, Aasarød K (2017)
Outcome in biopsy-proven Lupus nephritis: Evaluation of biopsies from the Norwegian Kidney Biopsy Registry
Lupus, 26 (8), 881-885
DOI 10.1177/0961203316686700, PubMed 28059018

Pihlstrøm HK, Gatti F, Hammarström C, Eide IA, Kasprzycka M, Wang J, Haraldsen G, Svensson MHS, Midtvedt K, Mjøen G, Dahle DO, Hartmann A, Holdaas H (2017)
Early introduction of oral paricalcitol in renal transplant recipients. An open-label randomized study
Transpl Int, 30 (8), 827-840
DOI 10.1111/tri.12973, PubMed 28436117

Rizvi SMH, Aagnes B, Holdaas H, Gude E, Boberg KM, Bjørtuft Ø, Helsing P, Leivestad T, Møller B, Gjersvik P (2017)
Long-term Change in the Risk of Skin Cancer After Organ Transplantation: A Population-Based Nationwide Cohort Study
JAMA Dermatol, 153 (12), 1270-1277
DOI 10.1001/jamadermatol.2017.2984, PubMed 29049612

Torres IB, Reisaeter AV, Moreso F, Âsberg A, Vidal M, Garcia-Carro C, Midtvedt K, Reinholt FP, Scott H, Castellà E, Salcedo M, Dörje C, Sellarés J, Azancot MA, Perello M, Holdaas H, Serón D (2017)
Tacrolimus and mycophenolate regimen and subclinical tubulo-interstitial inflammation in low immunological risk renal transplants
Transpl Int, 30 (11), 1119-1131
DOI 10.1111/tri.13002, PubMed 28667664

Wagner S, Apetrii M, Massy ZA, Kleber ME, Delgado GE, Scharnagel H, März W, Metzger M, Rossignol P, Jardine A, Holdaas H, Fellström B, Schmieder R, Stengel B, Zannad F, on behalf AURORA study group and F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) network (2017)
Oxidized LDL, statin use, morbidity, and mortality in patients receiving maintenance hemodialysis
Free Radic Res, 51 (1), 14-23
DOI 10.1080/10715762.2016.1241878, PubMed 27667446

Publications 2016

Cholesterol Treatment Trialists' (CTT) Collaboration, Herrington WG, Emberson J, Mihaylova B, Blackwell L, Reith C, Solbu MD, Mark PB, Fellström B, Jardine AG, Wanner C, Holdaas H, Fulcher J, Haynes R, Landray MJ, Keech A, Simes J, Collins R, Baigent C (2016)
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
Lancet Diabetes Endocrinol, 4 (10), 829-39
DOI 10.1016/S2213-8587(16)30156-5, PubMed 27477773

Dörje C, Reisaeter AV, Dahle DO, Mjøen G, Midtvedt K, Holdaas H, Flaa-Johnsen L, Syversveen T, Hartmann A, Jenssen T, Scott H, Reinholt FP (2016)
Total inflammation in early protocol kidney graft biopsies does not predict progression of fibrosis at one year post-transplant
Clin Transplant, 30 (7), 802-9
DOI 10.1111/ctr.12753, PubMed 27101801

Holdaas H, De Simone P, Zuckermann A (2016)
Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update
J Transplant, 2016, 4369574
DOI 10.1155/2016/4369574, PubMed 27807479

Mjøen G, Holdaas H (2016)
Regarding long-term outcome after kidney donation
Transpl Int, 29 (3), 381
DOI 10.1111/tri.12717, PubMed 26563683

Mjøen G, Holdaas H (2016)
Kidney-Failure Risk Projection for the Living Kidney-Donor Candidate
N Engl J Med, 374 (21), 2094
DOI 10.1056/NEJMc1603007, PubMed 27223156

Mjøen G, Reisaeter A, Hallan S, Line PD, Hartmann A, Midtvedt K, Foss A, Dahle DO, Holdaas H (2016)
Overall and cardiovascular mortality in Norwegian kidney donors compared to the background population
Nephrol Dial Transplant, 31 (1), 170
DOI 10.1093/ndt/gfv397, PubMed 26740671

Pihlstrøm HK, Mjøen G, Mucha S, Haraldsen G, Franke A, Jardine A, Fellström B, Holdaas H, Melum E (2016)
Single Nucleotide Polymorphisms and Long-Term Clinical Outcome in Renal Transplant Patients: A Validation Study
Am J Transplant, 17 (2), 528-533
DOI 10.1111/ajt.13995, PubMed 27483393

Størset E, Åsberg A, Hartmann A, Reisaeter AV, Holdaas H, Skauby M, Bergan S, Midtvedt K (2016)
Low-target tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience
Nephrology (Carlton), 21 (10), 821-7
DOI 10.1111/nep.12738, PubMed 26854648

Publications 2015

Dahle DO, Eide IA, Åsberg A, Leivestad T, Holdaas H, Jenssen TG, Fagerland MW, Pihlstrøm H, Mjøen G, Hartmann A (2015)
Aortic Stiffness in a Mortality Risk Calculator for Kidney Transplant Recipients
Transplantation, 99 (8), 1730-7
DOI 10.1097/TP.0000000000000660, PubMed 25757216

Dahle DO, Åsberg A, Hartmann A, Holdaas H, Bachtler M, Jenssen TG, Dionisi M, Pasch A (2015)
Serum Calcification Propensity Is a Strong and Independent Determinant of Cardiac and All-Cause Mortality in Kidney Transplant Recipients
Am J Transplant, 16 (1), 204-12
DOI 10.1111/ajt.13443, PubMed 26375609

Drechsler C, Pihlstrøm H, Meinitzer A, Pilz S, Tomaschitz A, Abedini S, Fellstrom B, Jardine AG, Wanner C, März W, Holdaas H (2015)
Homoarginine and Clinical Outcomes in Renal Transplant Recipients: Results From the Assessment of Lescol in Renal Transplantation Study
Transplantation, 99 (7), 1470-6
DOI 10.1097/TP.0000000000000568, PubMed 25675199

Dörje C, Mjøen G, Strøm EH, Holdaas H, Jenssen T, Øyen O, Akkök ÇA, Cvancarova M, Midtvedt K, Reisaeter AV (2015)
One-year protocol biopsies from ABO-incompatible renal allografts compared with a matched cohort of ABO-compatible allografts
Clin Transplant, 29 (3), 268-76
DOI 10.1111/ctr.12515, PubMed 25644963

Lindahl JP, Hartmann A, Aakhus S, Endresen K, Midtvedt K, Holdaas H, Leivestad T, Horneland R, Øyen O, Jenssen T (2015)
Long-term cardiovascular outcomes in type 1 diabetic patients after simultaneous pancreas and kidney transplantation compared with living donor kidney transplantation
Diabetologia, 59 (4), 844-52
DOI 10.1007/s00125-015-3853-8, PubMed 26713324

Mjøen G, Holdaas H (2015)
The authors reply:
Kidney Int, 87 (3), 660
DOI 10.1038/ki.2014.400, PubMed 25723634

Murbraech K, Massey R, Undset LH, Midtvedt K, Holdaas H, Aakhus S (2015)
Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients--a three-yr serial echocardiographic substudy of the randomized controlled CENTRAL trial
Clin Transplant, 29 (8), 678-84
DOI 10.1111/ctr.12565, PubMed 25982053

Pihlstrøm H, Dahle DO, Mjøen G, Pilz S, März W, Abedini S, Holme I, Fellström B, Jardine AG, Holdaas H (2015)
Increased risk of all-cause mortality and renal graft loss in stable renal transplant recipients with hyperparathyroidism
Transplantation, 99 (2), 351-9
DOI 10.1097/TP.0000000000000583, PubMed 25594550

Publications 2014

Apeland T, Holdaas H, Mansoor MA (2014)
Kidney donors and kidney transplants have abnormal aminothiol redox status, and are at increased risk of oxidative stress and reduced redox buffer capacity
Clin Biochem, 47 (6), 378-82
DOI 10.1016/j.clinbiochem.2014.02.003, PubMed 24530370

Aulie HA, Selvaag AM, Günther A, Lilleby V, Molberg Ø, Hartmann A, Holdaas H, Flatø B (2014)
Arterial haemodynamics and coronary artery calcification in adult patients with juvenile idiopathic arthritis
Ann Rheum Dis, 74 (8), 1515-21
DOI 10.1136/annrheumdis-2013-204804, PubMed 24695010

Dahle DO, Jenssen T, Holdaas H, Asberg A, Soveri I, Holme I, Mjøen G, Eide IA, Pihlstrøm H, Dörje C, Halden TA, Hartmann A (2014)
Uric acid and clinical correlates of endothelial function in kidney transplant recipients
Clin Transplant, 28 (10), 1167-76
DOI 10.1111/ctr.12435, PubMed 25124959

Evenepoel P, Cooper K, Holdaas H, Messa P, Mourad G, Olgaard K, Rutkowski B, Schaefer H, Deng H, Torregrosa JV, Wuthrich RP, Yue S (2014)
A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism
Am J Transplant, 14 (11), 2545-55
DOI 10.1111/ajt.12911, PubMed 25225081

Holdaas H, Jardine AG (2014)
BP targets in renal transplant recipients: too high or too low?
J Am Soc Nephrol, 25 (7), 1371-3
DOI 10.1681/ASN.2014020177, PubMed 24627350

Holdaas H, Mjoen G (2014)
Long-term risks of kidney donation: age known
Am J Transplant, 14 (11), 2671-2
DOI 10.1111/ajt.12971, PubMed 25293790

Holdaas H, Potena L, Saliba F (2014)
mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern?
Transplant Rev (Orlando), 29 (2), 93-102
DOI 10.1016/j.trre.2014.08.003, PubMed 25227328

Lindahl JP, Reinholt FP, Eide IA, Hartmann A, Midtvedt K, Holdaas H, Dorg LT, Reine TM, Kolset SO, Horneland R, Øyen O, Brabrand K, Jenssen T (2014)
In patients with type 1 diabetes simultaneous pancreas and kidney transplantation preserves long-term kidney graft ultrastructure and function better than transplantation of kidney alone
Diabetologia, 57 (11), 2357-65
DOI 10.1007/s00125-014-3353-2, PubMed 25145544

Mjøen G, Hallan S, Dekker FW, Holdaas H (2014)
The authors reply
Kidney Int, 86 (3), 650
DOI 10.1038/ki.2014.148, PubMed 25168504

Mjøen G, Hallan S, Holdaas H (2014)
The authors reply:
Kidney Int, 85 (5), 1241-2
DOI 10.1038/ki.2014.37, PubMed 24786884

Mjøen G, Holdaas H (2014)
The authors reply
Kidney Int, 86 (2), 447
DOI 10.1038/ki.2014.149, PubMed 25079028

Mjøen G, Holdaas H (2014)
Selecting appropriate controls for kidney donors
Am J Transplant, 15 (1), 286
DOI 10.1111/ajt.13016, PubMed 25363214

Mjörnstedt L, Schwartz Sørensen S, von Zur Mühlen B, Jespersen B, Hansen JM, Bistrup C, Andersson H, Gustafsson B, Solbu D, Holdaas H (2014)
Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation
Transpl Int, 28 (1), 42-51
DOI 10.1111/tri.12437, PubMed 25176389

Murbraech K, Holdaas H, Massey R, Undset LH, Aakhus S (2014)
Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients: an echocardiographic substudy of the randomized controlled CENTRAL trial
Transplantation, 97 (2), 184-8
DOI 10.1097/TP.0b013e3182a92728, PubMed 24092385

Pihlstrøm H, Mjøen G, Dahle DO, Pilz S, Midtvedt K, März W, Abedini S, Holme I, Fellström B, Jardine A, Holdaas H (2014)
Symmetric dimethylarginine as predictor of graft loss and all-cause mortality in renal transplant recipients
Transplantation, 98 (11), 1219-25
DOI 10.1097/TP.0000000000000205, PubMed 24999963

Robertsen I, Asberg A, Granseth T, Vethe NT, Akhlaghi F, Ghareeb M, Molden E, Reier-Nilsen M, Holdaas H, Midtvedt K (2014)
More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients
Transplantation, 97 (12), 1266-71
DOI 10.1097/01.TP.0000443225.66960.7e, PubMed 24521776

Publications 2013

Dahle DO, Jenssen T, Holdaas H, Leivestad T, Vårdal M, Mjøen G, Reisaeter AV, Toft I, Hartmann A (2013)
Uric acid has a J-shaped association with cardiovascular and all-cause mortality in kidney transplant recipients
Clin Transplant, 28 (1), 134-40
DOI 10.1111/ctr.12290, PubMed 24372653

Dahle DO, Midtvedt K, Hartmann A, Jenssen T, Holdaas H, Mjøen G, Leivestad T, Asberg A (2013)
Endothelial dysfunction is associated with graft loss in renal transplant recipients
Transplantation, 95 (5), 733-9
DOI 10.1097/TP.0b013e31827d6312, PubMed 23364481

Dörje C, Midtvedt K, Holdaas H, Naper C, Strøm EH, Øyen O, Leivestad T, Aronsen T, Jenssen T, Flaa-Johnsen L, Lindahl JP, Hartmann A, Reisæter AV (2013)
Early versus late acute antibody-mediated rejection in renal transplant recipients
Transplantation, 96 (1), 79-84
DOI 10.1097/TP.0b013e31829434d4, PubMed 23632391

Fellstrom B, Holdaas H, Jardine A (2013)
Functional cardiopulmonary exercise testing in potential renal transplant recipients
J Am Soc Nephrol, 25 (1), 8-9
DOI 10.1681/ASN.2013090996, PubMed 24231661

Lindahl JP, Hartmann A, Horneland R, Holdaas H, Reisæter AV, Midtvedt K, Leivestad T, Oyen O, Jenssen T (2013)
Improved patient survival with simultaneous pancreas and kidney transplantation in recipients with diabetic end-stage renal disease
Diabetologia, 56 (6), 1364-71
DOI 10.1007/s00125-013-2888-y, PubMed 23549518

Mjøen G, Hallan S, Hartmann A, Foss A, Midtvedt K, Øyen O, Reisæter A, Pfeffer P, Jenssen T, Leivestad T, Line PD, Øvrehus M, Dale DO, Pihlstrøm H, Holme I, Dekker FW, Holdaas H (2013)
Long-term risks for kidney donors
Kidney Int, 86 (1), 162-7
DOI 10.1038/ki.2013.460, PubMed 24284516

Schjelderup P, Dahle DO, Holdaas H, Mjøen G, Nordby G, Abedini S, Jardine A, Fellström B, Svensson M (2013)
Anemia is a predictor of graft loss but not cardiovascular events and all-cause mortality in renal transplant recipients: follow-up data from the ALERT study
Clin Transplant, 27 (6), E636-43
DOI 10.1111/ctr.12220, PubMed 23991916

Schneider A, Jardine AG, Schneider MP, Holdaas H, Holme I, Fellstroem BC, Zannad F, Schmieder RE, AURORA Study Group (2013)
Determinants of cardiovascular risk in haemodialysis patients: post hoc analyses of the AURORA study
Am J Nephrol, 37 (2), 144-51
DOI 10.1159/000346710, PubMed 23392089

Soveri I, Snyder J, Holdaas H, Holme I, Jardine AG, L'Italien GJ, Fellström B (2013)
The external validation of the cardiovascular risk equation for renal transplant recipients: applications to BENEFIT and BENEFIT-EXT trials
Transplantation, 95 (1), 142-7
DOI 10.1097/TP.0b013e31827722c9, PubMed 23192156

Publications 2012

Gjersvik P, Helsing P, Holdaas H, Bergan S (2012)
[Immunosuppressive drugs and the development of skin cancer after organ transplantation]
Tidsskr Nor Laegeforen, 132 (18), 2064-8
DOI 10.4045/tidsskr.12.0389, PubMed 23038197

Hartmann A, Jenssen T, Holdaas H (2012)
Diabetes, chronic kidney disease and cancer risk
Nephrol Dial Transplant, 27 (8), 3018-20
DOI 10.1093/ndt/gfs175, PubMed 22734106

Holdaas H, Jardine A (2012)
Chronic kidney disease: Do patients with CKD benefit from lipid-lowering therapy?
Nat Rev Nephrol, 8 (12), 684-5
DOI 10.1038/nrneph.2012.240, PubMed 23090449

Holdaas H, Midtvedt K, Åsberg A (2012)
A drug safety evaluation of everolimus in kidney transplantation
Expert Opin Drug Saf, 11 (6), 1013-22
DOI 10.1517/14740338.2012.722993, PubMed 22954349

Holme I, Fellström BC, Jardine AG, Hartmann A, Holdaas H (2012)
Model comparisons of competing risk and recurrent events for graft failure in renal transplant recipients
Clin J Am Soc Nephrol, 8 (2), 241-7
DOI 10.2215/CJN.03760412, PubMed 23160259

Loftheim H, Midtvedt K, Hartmann A, Reisæter AV, Falck P, Holdaas H, Jenssen T, Reubsaet L, Asberg A (2012)
Urinary proteomic shotgun approach for identification of potential acute rejection biomarkers in renal transplant recipients
Transplant Res, 1 (1), 9
DOI 10.1186/2047-1440-1-9, PubMed 23369437

Mjörnstedt L, Sørensen SS, von Zur Mühlen B, Jespersen B, Hansen JM, Bistrup C, Andersson H, Gustafsson B, Undset LH, Fagertun H, Solbu D, Holdaas H (2012)
Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation
Am J Transplant, 12 (10), 2744-53
DOI 10.1111/j.1600-6143.2012.04162.x, PubMed 22812414

Soveri I, Abedini S, Holdaas H, Jardine A, Eriksson N, Fellström B (2012)
Graft loss risk in renal transplant recipients with metabolic syndrome: subgroup analyses of the ALERT trial
J Nephrol, 25 (2), 245-54
DOI 10.5301/JN.2011.8450, PubMed 21725919

Soveri I, Holme I, Holdaas H, Budde K, Jardine AG, Fellström B (2012)
A cardiovascular risk calculator for renal transplant recipients
Transplantation, 94 (1), 57-62
DOI 10.1097/TP.0b013e3182516cdc, PubMed 22683851

Svensson M, Jardine A, Fellström B, Holdaas H (2012)
Prevention of cardiovascular disease after renal transplantation
Curr Opin Organ Transplant, 17 (4), 393-400
DOI 10.1097/MOT.0b013e3283560a3b, PubMed 22790074

Publications 2011

Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V et al. (2011)
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Lancet, 377 (9784), 2181-92
DOI 10.1016/S0140-6736(11)60739-3, PubMed 21663949

Brabrand K, Holdaas H, Gunther A, Midtvedt K (2011)
Spontaneous regression of initially elevated peak systolic velocity in renal transplant artery
Transpl Int, 24 (6), 555-9
DOI 10.1111/j.1432-2277.2011.01233.x, PubMed 21332581

Campistol JM, de Fijter JW, Nashan B, Holdaas H, Vítko S, Legendre C (2011)
Everolimus and long-term outcomes in renal transplantation
Transplantation, 92 (3 Suppl), S3-26
DOI 10.1097/TP.0b013e3182230900, PubMed 21799392

Dahle DO, Mjøen G, Oqvist B, Scharnagl H, Weihrauch G, Grammer T, März W, Abedini S, Norby GE, Holme I, Fellström B, Jardine A, Holdaas H (2011)
Inflammation-associated graft loss in renal transplant recipients
Nephrol Dial Transplant, 26 (11), 3756-61
DOI 10.1093/ndt/gfr163, PubMed 21511816

Holdaas H, Holme I, Schmieder RE, Jardine AG, Zannad F, Norby GE, Fellström BC, AURORA study group (2011)
Rosuvastatin in diabetic hemodialysis patients
J Am Soc Nephrol, 22 (7), 1335-41
DOI 10.1681/ASN.2010090987, PubMed 21566054

Holdaas H, Rostaing L, Serón D, Cole E, Chapman J, Fellstrøm B, Strom EH, Jardine A, Midtvedt K, Machein U, Ulbricht B, Karpov A, O'Connell PJ, ASCERTAIN Investigators (2011)
Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study
Transplantation, 92 (4), 410-8
DOI 10.1097/TP.0b013e318224c12d, PubMed 21697773

Holme I, Fellström BC, Jardin AG, Schmieder RE, Zannad F, Holdaas H (2011)
Prognostic model for total mortality in patients with haemodialysis from the Assessments of Survival and Cardiovascular Events (AURORA) study
J Intern Med, 271 (5), 463-71
DOI 10.1111/j.1365-2796.2011.02435.x, PubMed 21812843

Jardine AG, Gaston RS, Fellstrom BC, Holdaas H (2011)
Prevention of cardiovascular disease in adult recipients of kidney transplants
Lancet, 378 (9800), 1419-27
DOI 10.1016/S0140-6736(11)61334-2, PubMed 22000138

Midtvedt K, Holdaas H (2011)
Belatacept: BENEFIT to the kidney?
Am J Transplant, 11 (3), 633; author reply 634
DOI 10.1111/j.1600-6143.2010.03411.x, PubMed 21342454

Mjøen G, Oyen O, Midtvedt K, Dahle DO, Norby G, Holdaas H (2011)
Age, gender, and body mass index are associated with renal function after kidney donation
Clin Transplant, 25 (6), E579-83
DOI 10.1111/j.1399-0012.2011.01503.x, PubMed 21906171

Mjøen G, Reisaeter A, Hallan S, Line PD, Hartmann A, Midtvedt K, Foss A, Dahle DO, Holdaas H (2011)
Overall and cardiovascular mortality in Norwegian kidney donors compared to the background population
Nephrol Dial Transplant, 27 (1), 443-7
DOI 10.1093/ndt/gfr303, PubMed 21636826

Mjøen G, Stavem K, Westlie L, Midtvedt K, Fauchald P, Norby G, Holdaas H (2011)
Quality of life in kidney donors
Am J Transplant, 11 (6), 1315-9
DOI 10.1111/j.1600-6143.2011.03517.x, PubMed 21486387

März W, Genser B, Drechsler C, Krane V, Grammer TB, Ritz E, Stojakovic T, Scharnagl H, Winkler K, Holme I, Holdaas H, Wanner C, German Diabetes and Dialysis Study Investigators (2011)
Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis
Clin J Am Soc Nephrol, 6 (6), 1316-25
DOI 10.2215/CJN.09121010, PubMed 21493741

Norby GE, Günther A, Mjøen G, Andersen R, Dolgos S, Hartmann A, Holdaas H (2011)
Prevalence and risk factors for coronary artery calcification following kidney transplantation for systemic lupus erythematosus
Rheumatology (Oxford), 50 (9), 1659-64
DOI 10.1093/rheumatology/ker186, PubMed 21624893

Norby GE, Leivestad T, Mjøen G, Hartmann A, Midtvedt K, Gran JT, Holdaas H (2011)
Premature cardiovascular disease in patients with systemic lupus erythematosus influences survival after renal transplantation
Arthritis Rheum, 63 (3), 733-7
DOI 10.1002/art.30184, PubMed 21360503

Svensson M, Dahle DO, Mjøen G, Weihrauch G, Scharnagl H, Dobnig H, März W, Jardine A, Fellström B, Holdaas H (2011)
Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study
Nephrol Dial Transplant, 27 (6), 2571-5
DOI 10.1093/ndt/gfr694, PubMed 22172725

Publications 2010

Abedini S, Meinitzer A, Holme I, März W, Weihrauch G, Fellstrøm B, Jardine A, Holdaas H (2010)
Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients
Kidney Int, 77 (1), 44-50
DOI 10.1038/ki.2009.382, PubMed 19847152

Asberg A, Falck P, Undset LH, Dørje C, Holdaas H, Hartmann A, Midtvedt K (2010)
Computer-assisted cyclosporine dosing performs better than traditional dosing in renal transplant recipients: results of a pilot study
Ther Drug Monit, 32 (2), 152-8
DOI 10.1097/FTD.0b013e3181d3f822, PubMed 20216113

Gude E, Gullestad L, Arora S, Simonsen S, Hoel I, Hartmann A, Holdaas H, Fiane AE, Geiran OR, Andreassen AK (2010)
Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation
J Heart Lung Transplant, 29 (6), 641-7
DOI 10.1016/j.healun.2010.01.005, PubMed 20304681

McQuarrie EP, Fellström BC, Holdaas H, Jardine AG (2010)
Cardiovascular disease in renal transplant recipients
J Ren Care, 36 Suppl 1, 136-45
DOI 10.1111/j.1755-6686.2010.00160.x, PubMed 20586909

Mjoen G, Midtvedt K, Holme I, Øyen O, Fauchald P, Bergrem H, Holdaas H (2010)
One- and five-year follow-ups on blood pressure and renal function in kidney donors
Transpl Int, 24 (1), 73-7
DOI 10.1111/j.1432-2277.2010.01148.x, PubMed 20723180

Mjøen G, Holdaas H, Pfeffer P, Line PD, Øyen O (2010)
Minimally invasive living donor nephrectomy - introduction of hand-assistance
Transpl Int, 23 (10), 1008-14
DOI 10.1111/j.1432-2277.2010.01087.x, PubMed 20412538

Norby GE, Lerang K, Holdaas H, Gran JT, Strøm EH, Draganov B, Os I, Hartmann A, Gilboe IM (2010)
[Lupus-nephritis--diagnosis and treatment]
Tidsskr Nor Laegeforen, 130 (11), 1140-4
DOI 10.4045/tidsskr.09.0583, PubMed 20531500

Norby GE, Strøm EH, Midtvedt K, Hartmann A, Gilboe IM, Leivestad T, Stenstrøm J, Holdaas H (2010)
Recurrent lupus nephritis after kidney transplantation: a surveillance biopsy study
Ann Rheum Dis, 69 (8), 1484-7
DOI 10.1136/ard.2009.122796, PubMed 20498208

Publications 2009

Abedini S, Holme I, Fellström B, Jardine A, Cole E, Maes B, Holdaas H, ALERT Study Group (2009)
Cerebrovascular events in renal transplant recipients
Transplantation, 87 (1), 112-7
DOI 10.1097/TP.0b013e31818bfce8, PubMed 19136900

Abedini S, Holme I, März W, Weihrauch G, Fellström B, Jardine A, Cole E, Maes B, Neumayer HH, Grønhagen-Riska C, Ambühl P, Holdaas H, ALERT study group (2009)
Inflammation in renal transplantation
Clin J Am Soc Nephrol, 4 (7), 1246-54
DOI 10.2215/CJN.00930209, PubMed 19541816

Bremer S, Vethe NT, Rootwelt H, Jørgensen PF, Stenstrøm J, Holdaas H, Midtvedt K, Bergan S (2009)
Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study
J Transl Med, 7, 64
DOI 10.1186/1479-5876-7-64, PubMed 19635156

Falck P, Midtvedt K, Vân Lê TT, Storehagen L, Holdaas H, Hartmann A, Asberg A (2009)
A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients
Clin Pharmacokinet, 48 (9), 615-23
DOI 10.2165/11313380-000000000-00000, PubMed 19725595

Fellstrom B, Jardine A, Holdaas H, AURORA Executive Steering Comm (2009)
Rosuvastatin in Patients Undergoing Hemodialysis REPLY
N. Engl. J. Med., 361 (1), 94-95

Fellström B, Holdaas H, Jardine AG, Svensson MK, Gottlow M, Schmieder RE, Zannad F, AURORA Study Group (2009)
Cardiovascular disease in patients with renal disease: the role of statins
Curr Med Res Opin, 25 (1), 271-85
DOI 10.1185/03007990802622064, PubMed 19210158

Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP et al. (2009)
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis
N Engl J Med, 360 (14), 1395-407
DOI 10.1056/NEJMoa0810177, PubMed 19332456

Holme I, Fayyad R, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Holdaas H, Pedersen TR, Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group (2009)
Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial
J Intern Med, 267 (6), 567-75
DOI 10.1111/j.1365-2796.2009.02176.x, PubMed 20141566

Holme I, Fellstrom B, Jardine A, Holdaas H (2009)
Comparison of predictive ability of lipoprotein components to that of traditional risk factors of coronary events in renal transplant recipients
Atherosclerosis, 208 (1), 234-9
DOI 10.1016/j.atherosclerosis.2009.06.020, PubMed 19596331

Midtvedt K, Bitter J, Dørje C, Bjørneklett R, Holdaas H (2009)
Belatacept as immunosuppression in patient with recurrence of hemolytic uremic syndrome after renal transplantation
Transplantation, 87 (12), 1901-3
DOI 10.1097/TP.0b013e3181a991ca, PubMed 19543075

Mjøen G, Øyen O, Holdaas H, Midtvedt K, Line PD (2009)
Morbidity and mortality in 1022 consecutive living donor nephrectomies: benefits of a living donor registry
Transplantation, 88 (11), 1273-9
DOI 10.1097/TP.0b013e3181bb44fd, PubMed 19996926

Norby GE, Holme I, Fellström B, Jardine A, Cole E, Abedini S, Holdaas H, Assessment of Lescol in Renal Transplantation Study Group (2009)
Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study
Arthritis Rheum, 60 (4), 1060-4
DOI 10.1002/art.24379, PubMed 19333947

Soveri I, Abedini S, Holdaas H, Jardine A, Eriksson N, Fellström B (2009)
Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment
Clin Transplant, 23 (6), 914-20
DOI 10.1111/j.1399-0012.2009.01025.x, PubMed 19594771

Valderhaug TG, Jenssen T, Hartmann A, Midtvedt K, Holdaas H, Reisaeter AV, Hjelmesaeth J (2009)
Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation
Transplantation, 88 (3), 429-34
DOI 10.1097/TP.0b013e3181af1f53, PubMed 19667949

Witczak BJ, Leivestad T, Line PD, Holdaas H, Reisaeter AV, Jenssen TG, Midtvedt K, Bitter J, Hartmann A (2009)
Experience from an active preemptive kidney transplantation program--809 cases revisited
Transplantation, 88 (5), 672-7
DOI 10.1097/TP.0b013e3181b27b7e, PubMed 19741464

Aasebø W, Midtvedt K, Valderhaug TG, Leivestad T, Hartmann A, Reisaeter AV, Jenssen T, Holdaas H (2009)
Impaired glucose homeostasis in renal transplant recipients receiving basiliximab
Nephrol Dial Transplant, 25 (4), 1289-93
DOI 10.1093/ndt/gfp617, PubMed 19934089

Publications 2008

Esnault VL, Brown EA, Apetrei E, Bagon J, Calvo C, DeChatel R, Holdaas H, Krcmery S, Kobalava Z, Amlodipine Versus Enalapril in Renal failure (AVER) Study Group (2008)
The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study
Clin Ther, 30 (3), 482-98
DOI 10.1016/j.clinthera.2008.03.006, PubMed 18405787

Foss A, Gunther A, Line PD, Brabrand K, Holdaas H, Hartmann A, Midtvedt K (2008)
Long-term clinical outcome of paediatric kidneys transplanted to adults
Nephrol Dial Transplant, 23 (2), 726-9
DOI 10.1093/ndt/gfm826, PubMed 18198285

Gunther A, Foss A, Holdaas H, Brabrand K, Hartmann A, Line PD, Midtvedt K (2008)
Increased peak systolic velocity in the renal artery of paediatric kidneys transplanted to adult recipients
Nephrol Dial Transplant, 23 (12), 4041-3
DOI 10.1093/ndt/gfn358, PubMed 18586763

Holdaas H (2008)
Statin therapy for prevention of coronary artery disease. The earlier the better or the longer the better?
Eur Heart J, 29 (4), 425-6
DOI 10.1093/eurheartj/ehm628, PubMed 18276612

Holdaas H, Bentdal O, Pfeffer P, Mjørnstedt L, Solbu D, Midtvedt K (2008)
Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study
Clin Transplant, 22 (3), 366-71
DOI 10.1111/j.1399-0012.2008.00795.x, PubMed 18279419

Publications 2007

Ekberg H, Kyllönen L, Madsen S, Grave G, Solbu D, Holdaas H (2007)
Increased prevalence of gastrointestinal symptoms associated with impaired quality of life in renal transplant recipients
Transplantation, 83 (3), 282-9
DOI 10.1097/01.tp.0000251923.14697.f5, PubMed 17297402

Ekberg H, Kyllönen L, Madsen S, Grave G, Solbu D, Holdaas H (2007)
Clinicians underestimate gastrointestinal symptoms and overestimate quality of life in renal transplant recipients: a multinational survey of nephrologists
Transplantation, 84 (8), 1052-4
DOI 10.1097/01.tp.0000284983.89207.1a, PubMed 17989612

Falck P, Vethe NT, Asberg A, Midtvedt K, Bergan S, Reubsaet JL, Holdaas H (2007)
Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients
Nephrol Dial Transplant, 23 (3), 1048-53
DOI 10.1093/ndt/gfm632, PubMed 17956893

Fellström B, Holdaas H, Jardine AG, Rose H, Schmieder R, Wilpshaar W, Zannad F, AURORA Study Group (2007)
Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study
Kidney Blood Press Res, 30 (5), 314-22
DOI 10.1159/000106803, PubMed 17671394

Singer JB, Holdaas H, Jardine AG, Fellstrøm B, Os I, Bermann G, Meyer JM, Assessment of Lescol in Renal Transplantation (ALERT) Study Investigators (2007)
Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients
J Lipid Res, 48 (9), 2072-8
DOI 10.1194/jlr.M700076-JLR200, PubMed 17563401

Publications 2006

Asberg A, Midtvedt K, Line PD, Narverud J, Holdaas H, Jenssen T, Reisaeter AV, Johnsen LF, Fauchald P, Hartmann A (2006)
Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients
Transplantation, 82 (1), 62-8
DOI 10.1097/01.tp.0000225803.04995.2b, PubMed 16861943

Fellström B, Abedini S, Holdaas H, Jardine AG, Staffler B, Gimpelewicz C, Assessment of Lescol in Renal Transplantation (ALERT) study group (2006)
No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study
Clin Transplant, 20 (6), 732-9
DOI 10.1111/j.1399-0012.2006.00555.x, PubMed 17100723

Hartmann A, Holdaas H, Os I, Hunderi OH, Hallan S, Widerøe TE, Svarstad E, Selvig K, Skjønsberg H, Toft I (2006)
[Staging and measurement of renal function in chronic renal conditions]
Tidsskr Nor Laegeforen, 126 (9), 1198-200
PubMed 16670740

Hjelmesaeth J, Hartmann A, Leivestad T, Holdaas H, Sagedal S, Olstad M, Jenssen T (2006)
The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events
Kidney Int, 69 (3), 588-95
DOI 10.1038/sj.ki.5000116, PubMed 16395250

Holdaas H, Hagen E, Asberg A, Lund K, Hartman A, Vaidyanathan S, Prasad P, He YL, Yeh CM, Bigler H, Rouilly M, Denouel J (2006)
Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients
Int J Clin Pharmacol Ther, 44 (4), 163-71
DOI 10.5414/cpp44163, PubMed 16625985

Holdaas H, Singh D (2006)
Fluvastatin may be similarly effective in older and younger people
Evid Based Cardiovasc Med, 10 (1), 11-2
DOI 10.1016/j.ebcm.2006.01.001, PubMed 16530657

Holdaas H, Wanner C, Abletshauser C, Gimpelewicz C, Isaacsohn J (2006)
The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials
Int J Cardiol, 117 (1), 64-74
DOI 10.1016/j.ijcard.2006.06.003, PubMed 16889855

Holdaas H, Wanner C, Abletshauser C, Gimpelewicz C, Isaacsohn J (2006)
The renal safety profile of fluvastatin: results of a pooled analysis
Ren Fail, 28 (6), 487-92
DOI 10.1080/08860220600781260, PubMed 16928618

Holdaas H, Westlie L (2006)
[A renaissance for home hemodialysis?]
Tidsskr Nor Laegeforen, 126 (21), 2785
PubMed 17086216

Oien CM, Reisaeter AV, Os I, Jardine A, Fellström B, Holdaas H (2006)
Gender-associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study
Clin Transplant, 20 (3), 374-82
DOI 10.1111/j.1399-0012.2006.00496.x, PubMed 16824157

Soveri I, Holdaas H, Jardine A, Gimpelewicz C, Staffler B, Fellström B (2006)
Renal transplant dysfunction--importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality
Nephrol Dial Transplant, 21 (8), 2282-9
DOI 10.1093/ndt/gfl095, PubMed 16574686

Publications 2005

Corsini A, Holdaas H (2005)
Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation
Ren Fail, 27 (3), 259-73
DOI 10.1081/JDI-200056623, PubMed 15957541

Fellström B, Holdaas H, Jardine AG, Nyberg G, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Staffler B, Pedersen TR, Assessment of Lescol in Renal Transplantation Study Investigators (2005)
Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial
Transplantation, 79 (2), 205-12
DOI 10.1097/01.tp.0000147338.34323.12, PubMed 15665769

Fellström B, Jardine AG, Soveri I, Cole E, Grönhagen-Riska C, Neumayer HH, Maes B, Gimpelewicz C, Holdaas H, Assessment of Lescol in Renal Transplantation trial (2005)
Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial
Transplantation, 79 (9), 1160-3
DOI 10.1097/01.tp.0000160764.35083.b8, PubMed 15880062

Fellström B, Jardine AG, Soveri I, Cole E, Neumayer HH, Maes B, Gimpelewicz C, Holdaas H, ALERT Study Group (2005)
Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation
Am J Transplant, 5 (8), 1986-91
DOI 10.1111/j.1600-6143.2005.00983.x, PubMed 15996249

Fellström B, Zannad F, Schmieder R, Holdaas H, Jardine A, Rose H, Wilpshaar W, AURORA Study Group (2005)
Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study
Curr Control Trials Cardiovasc Med, 6 (1), 9
DOI 10.1186/1468-6708-6-9, PubMed 15910680

Hermann M, Asberg A, Christensen H, Reubsaet JL, Holdaas H, Hartmann A (2005)
Atorvastatin does not affect the pharmacokinetics of cyclosporine in renal transplant recipients
Eur J Clin Pharmacol, 61 (1), 59-62
DOI 10.1007/s00228-004-0874-5, PubMed 15711834

Holdaas H (2005)
Preventing cardiovascular outcome in patients with renal impairment: is there a role for lipid-lowering therapy?
Am J Cardiovasc Drugs, 5 (4), 255-69
DOI 10.2165/00129784-200505040-00005, PubMed 15984908

Holdaas H, Fellström B, Cole E, Nyberg G, Olsson AG, Pedersen TR, Madsen S, Grönhagen-Riska C, Neumayer HH, Maes B, Ambühl P, Hartmann A, Staffler B, Jardine AG, Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators (2005)
Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study
Am J Transplant, 5 (12), 2929-36
DOI 10.1111/j.1600-6143.2005.01105.x, PubMed 16303007

Holdaas H, Fellström B, Jardine AG, ALERT Study Group (2005)
Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: lessons to be learnt from the assessment of Lescol in renal transplantation (ALERT) trial
Am J Transplant, 5 (6), 1574-5
DOI 10.1111/j.1600-6143.2005.00909.x, PubMed 15888072

Holdaas H, Fellström B, Jardine AG, Nyberg G, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Logan JO, Staffler B, Gimpelewicz C, ALERT Study Group (2005)
Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation
Nephrol Dial Transplant, 20 (5), 974-80
DOI 10.1093/ndt/gfh735, PubMed 15784644

Jardine AG, Fellström B, Logan JO, Cole E, Nyberg G, Grönhagen-Riska C, Madsen S, Neumayer HH, Maes B, Ambühl P, Olsson AG, Pedersen T, Holdaas H (2005)
Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study
Am J Kidney Dis, 46 (3), 529-36
DOI 10.1053/j.ajkd.2005.05.014, PubMed 16129216

Lemahieu WP, Hermann M, Asberg A, Verbeke K, Holdaas H, Vanrenterghem Y, Maes BD (2005)
Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus
Am J Transplant, 5 (9), 2236-43
DOI 10.1111/j.1600-6143.2005.01005.x, PubMed 16095503

Publications 2004

Asberg A, Holdaas H (2004)
Fluvastatin and fluvastatin extended release: a clinical and safety profile
Expert Rev Cardiovasc Ther, 2 (5), 641-52
DOI 10.1586/14779072.2.5.641, PubMed 15350166

Fellström B, Holdaas H, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Hartmann A, Logan JO, Pedersen TR, Assessment of Lescol in Renal Transplantation Study Investigators (2004)
Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial
Kidney Int, 66 (4), 1549-55
DOI 10.1111/j.1523-1755.2004.00919.x, PubMed 15458450

Hermann M, Asberg A, Christensen H, Holdaas H, Hartmann A, Reubsaet JL (2004)
Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients
Clin Pharmacol Ther, 76 (4), 388-91
DOI 10.1016/j.clpt.2004.07.008, PubMed 15470339

Jardine AG, Holdaas H, Fellström B, Cole E, Nyberg G, Grönhagen-Riska C, Madsen S, Neumayer HH, Maes B, Ambühl P, Olsson AG, Holme I, Fauchald P, Gimpelwicz C, Pedersen TR, ALERT Study Investigators (2004)
fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study
Am J Transplant, 4 (6), 988-95
DOI 10.1111/j.1600-6143.2004.00445.x, PubMed 15147434

Publications 2003

Asberg A, Holdaas H, Jardine AG, Edvardsen C, Hartmann A (2003)
Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation
Clin Transplant, 17 (4), 385-90
DOI 10.1034/j.1399-0012.2003.00063.x, PubMed 12868997

Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, März W, Reckless JP, Stein EA (2003)
Risk for myopathy with statin therapy in high-risk patients
Arch Intern Med, 163 (5), 553-64
DOI 10.1001/archinte.163.5.553, PubMed 12622602

Fellström BC, Holdaas H, Jardine AG (2003)
Why do we need a statin trial in hemodialysis patients?
Kidney Int Suppl (84), S204-6
DOI 10.1046/j.1523-1755.63.s84.10.x, PubMed 12694345

Hartmann A, Fauchald P, Westlie L, Brekke IB, Holdaas H (2003)
The risk of living kidney donation
Nephrol Dial Transplant, 18 (5), 871-3
DOI 10.1093/ndt/gfg069, PubMed 12686656

Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR, Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators (2003)
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial
Lancet, 361 (9374), 2024-31
DOI 10.1016/S0140-6736(03)13638-0, PubMed 12814712

Holdaas H, Jardine A (2003)
Acute renal allograft rejections, a role for statins?
Minerva Urol Nefrol, 55 (2), 111-9
PubMed 12847415

Jakobsen A, Holdaas H, Leivestad T (2003)
Ethics and safety of living kidney donation
Transplant Proc, 35 (3), 1177-8
DOI 10.1016/s0041-1345(03)00136-2, PubMed 12947899

Westlie L, Leivestad T, Holdaas H, Lien B, Hartmann A, Fauchald P (2003)
[Is current practice concerning living donors in kidney transplantations acceptable?]
Tidsskr Nor Laegeforen, 123 (8), 1063-5
PubMed 12760222

Westlie L, Leivestad T, Holdaas H, Lien B, Meyer K, Fauchald P (2003)
[How are living kidney donors doing?]
Tidsskr Nor Laegeforen, 123 (8), 1060-2
PubMed 12760221

Westlie L, Leivestad T, Holdaas H, Lien B, Meyer K, Fauchald P (2003)
Report from the Norwegian National Hospitals Living Donor Registry: one-year data, January 1, 2002
Transplant Proc, 35 (2), 777-8
DOI 10.1016/s0041-1345(03)00039-3, PubMed 12644132

Publications 2002

Holdaas H, Julian D (2002)
The use of statins after solid organ transplantation
Nephrol Dial Transplant, 17 (8), 1537
DOI 10.1093/ndt/17.8.1537, PubMed 12147814

Os I, Stenehjem A, Høieggen A, Draganov B, Jenssen T, Holdaas H (2002)
[Type 2 diabetes and nephropathy--new studies, new treatment strategies?]
Tidsskr Nor Laegeforen, 122 (9), 918-20
PubMed 12082835

Publications 2001

Asberg A, Hartmann A, Fjeldså E, Bergan S, Holdaas H (2001)
Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients
Am J Transplant, 1 (4), 382-6
DOI 10.1034/j.1600-6143.2001.10415.x, PubMed 12099384

Asberg A, Hartmann A, Fjeldså E, Holdaas H (2001)
Atorvastatin improves endothelial function in renal-transplant recipients
Nephrol Dial Transplant, 16 (9), 1920-4
DOI 10.1093/ndt/16.9.1920, PubMed 11522880

Holdaas H, Fellström B, Holme I, Nyberg G, Fauchald P, Jardine A, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Weinreich T, Olsson AG, Pedersen TR, Benghozi R, Hartmann A, ALERT Study Group. Assessment of Lescol in Renal Transplantation (2001)
Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data
J Cardiovasc Risk, 8 (2), 63-71
DOI 10.1177/174182670100800202, PubMed 11324372

Holdaas H, Jardine AG, Wheeler DC, Brekke IB, Conlon PJ, Fellstrøm B, Hammad A, Holme I, Isoniemi H, Moore R, Rowe PA, Sweny P, Talbot DA, Wadstrøm J, Østraat Ø (2001)
Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial
Kidney Int, 60 (5), 1990-7
DOI 10.1046/j.1523-1755.2001.00010.x, PubMed 11703619

Linde T, Ekberg H, Forslund T, Furuland H, Holdaas H, Nyberg G, Tydén G, Wahlberg J, Danielson BG (2001)
The use of pretransplant erythropoietin to normalize hemoglobin levels has no deleterious effects on renal transplantation outcome
Transplantation, 71 (1), 79-82
DOI 10.1097/00007890-200101150-00013, PubMed 11211199

Midtvedt K, Hartmann A, Foss A, Fauchald P, Nordal KP, Rootwelt K, Holdaas H (2001)
Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril
Transplantation, 72 (11), 1787-92
DOI 10.1097/00007890-200112150-00013, PubMed 11740389

Midtvedt K, Hartmann A, Holdaas H, Fauchald P (2001)
Efficacy of nifedipine or lisinopril in the treatment of hypertension after renal transplantation: a double-blind randomised comparative trial
Clin Transplant, 15 (6), 426-31
DOI 10.1034/j.1399-0012.2001.150611.x, PubMed 11737121

Midtvedt K, Ihlen H, Hartmann A, Bryde P, Bjerkely BL, Foss A, Fauchald P, Holdaas H (2001)
Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study
Transplantation, 72 (1), 107-11
DOI 10.1097/00007890-200107150-00021, PubMed 11468543

Publications 1999

Jardine A, Holdaas H (1999)
Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience
J Clin Pharm Ther, 24 (6), 397-408
DOI 10.1046/j.1365-2710.1999.00252.x, PubMed 10651972

Publications 1998

Holdaas H, Hartmann A, Berg KJ, Lund K, Fauchald P (1998)
Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy
Nephrol Dial Transplant, 13 (12), 3096-102
DOI 10.1093/ndt/13.12.3096, PubMed 9870472

Publications 1996

Hartmann A, Andereassen AK, Holdaas H, Simonsen S, Geiran O, Berg KJ (1996)
Five years' follow-up of renal glomerular and tubular functions in heart transplant recipients
J Heart Lung Transplant, 15 (10), 972-9
PubMed 8913913

Midtvedt K, Tafjord AB, Hartmann A, Eide TC, Holdaas H, Nordal KP, Draganov B, Sødal G, Leivestad T, Fauchald P (1996)
Half dose of OKT3 is efficient in treatment of steroid-resistant renal allograft rejection
Transplantation, 62 (1), 38-42
DOI 10.1097/00007890-199607150-00008, PubMed 8693541

Nyberg G, Holdaas H, Brekke IB, Hartmenn A, Norden G, Olausson M, Osterby R (1996)
Glomerular ultrastructure in kidneys transplanted simultaneously with a segmental pancreas to patients with type 1 diabetes
Nephrol Dial Transplant, 11 (6), 1029-33
PubMed 8671964

Publications 1995

Brekke IB, Bentdal O, Pfeffer P, Lien B, Sødal G, Holdaas H, Fauchald P, Jervell J (1995)
[Pancreas transplantation. A 10-year material]
Tidsskr Nor Laegeforen, 115 (6), 703-5
PubMed 7900130

Holdaas H, Hartmann A, Berg KJ, Langberg H, Blystad L, Fauchald P (1995)
Contrasting effects of angiotensin converting inhibitor and alpha-1-antagonist on albuminuria in insulin-dependent diabetes mellitus patients with nephropathy
J Intern Med, 237 (1), 63-71
DOI 10.1111/j.1365-2796.1995.tb01141.x, PubMed 7830033

Holdaas H, Hartmann A, Stenstrøm J, Dahl KJ, Borge M, Pfister P (1995)
Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine
Am J Cardiol, 76 (2), 102A-106A
DOI 10.1016/s0002-9149(05)80028-1, PubMed 7604781

Reisaeter AV, Leivestad T, Albrechtsen D, Holdaas H, Hartmann A, Sødal G, Flatmark A, Fauchald P (1995)
Pretransplant plasma exchange or immunoadsorption facilitates renal transplantation in immunized patients
Transplantation, 60 (3), 242-8
DOI 10.1097/00007890-199508000-00006, PubMed 7645036

Tonstad S, Holdaas H, Gørbitz C, Ose L (1995)
Is dietary intervention effective in post-transplant hyperlipidaemia?
Nephrol Dial Transplant, 10 (1), 82-5
PubMed 7724035

Publications 1994

Bentdal OH, Brekke IB, Lien B, Pfeffer PF, Sødal G, Hartmann A, Holdaas H, Nordal KP, Fauchald P (1994)
Rapid development of cancer in both kidney grafts after transplantation from a donor with undiagnosed malignant disease
Transplant Proc, 26 (3), 1763
PubMed 8030123

Hartmann A, Lund K, Holdaas H, Fauchald P, Reisaeter A, Berg KJ (1994)
Contrasting short-term effects of nifedipine on glomerular and tubular functions in glomerulonephritic patients
J Am Soc Nephrol, 5 (6), 1385-90
PubMed 7534496

Hartmann A, Reisaeter A, Holdaas H, Rolfsen B, Fauchald P (1994)
Accidental metabolic acidosis during hemodialysis
Artif Organs, 18 (3), 214-7
DOI 10.1111/j.1525-1594.1994.tb02178.x, PubMed 8185487

Holdaas H, Andersson R, Fauchald P, Albrechtsen D (1994)
[Infection in patients with organ transplants]
Nord Med, 109 (6-7), 194-6
PubMed 8015915

Reisaeter AV, Fauchald P, Leivestad T, Holdaas H, Hartmann A, Pfeffer P, Sødal G (1994)
Plasma exchange in highly sensitized patients as induction therapy after renal transplantation
Transplant Proc, 26 (3), 1758
PubMed 8030121

Publications 1992

Fauchald P, Vatne K, Paulsen D, Brodahl U, Sødal G, Holdaas H, Berg KJ, Flatmark A (1992)
Long-term clinical results of percutaneous transluminal angioplasty in transplant renal artery stenosis
Nephrol Dial Transplant, 7 (3), 256-9
DOI 10.1093/oxfordjournals.ndt.a092116, PubMed 1315000

Hartmann A, Holdaas H, Fauchald P, Nordal KP, Berg KJ, Talseth T, Leivestad T, Brekke IB, Flatmark A (1992)
Fifteen years' experience with renal transplantation in systemic amyloidosis
Transpl Int, 5 (1), 15-8
DOI 10.1007/bf00337183, PubMed 1580980

Publications 1991

Bentdal OH, Fauchald P, Brekke IB, Holdaas H, Hartmann A (1991)
Rehabilitation and quality of life in diabetic patients after successful pancreas-kidney transplantation
Diabetologia, 34 Suppl 1, S158-9
DOI 10.1007/bf00587645, PubMed 1936685

Berg KJ, Holdaas H, Endresen L, Fauchald P, Hartmann A, Pran T, Solbu D (1991)
Effects of isradipine on renal function in cyclosporin-treated renal transplanted patients
Nephrol Dial Transplant, 6 (10), 725-30
DOI 10.1093/ndt/6.10.725, PubMed 1836548

Endresen L, Bergan S, Holdaas H, Pran T, Sinding-Larsen B, Berg KJ (1991)
Lack of effect of the calcium antagonist isradipine on cyclosporine pharmacokinetics in renal transplant patients
Ther Drug Monit, 13 (6), 490-5
DOI 10.1097/00007691-199111000-00004, PubMed 1837629

Hartmann A, Charania B, Sund S, Holdaas H, Fauchald P, Flatmark A (1991)
Interstitial nephritis with extensive calcium deposits as a cause of renal allograft failure
Nephrol Dial Transplant, 6 (12), 984-8
DOI 10.1093/ndt/6.12.984, PubMed 1798600

Hartmann A, Holdaas H (1991)
[Therapeutic principles in hyperkalemia]
Tidsskr Nor Laegeforen, 111 (18), 2275-7
PubMed 1896986

Holdaas H, Brekke IB, Hartmann A, Bentdal OH, Ganes T, Gjellestad A, Fauchald P, Berg KJ, Djøseland O, Jervell J (1991)
Long-term metabolic control in recipients of combined pancreas and kidney transplants
Diabetologia, 34 Suppl 1, S68-70
DOI 10.1007/bf00587623, PubMed 1936699

Holdaas H, Brekke IB, Hartmann A, Fauchald P, Bentdal O, Søodal G, Jervell J, Flatmark A (1991)
Long-term glucose control following combined kidney and pancreatic transplantation
Transplant Proc, 23 (1 Pt 2), 1656-7
PubMed 1989322

Holdaas H, Hartmann A, Lien MG, Nilsen L, Jervell J, Fauchald P, Endresen L, Djøseland O, Berg KJ (1991)
Contrasting effects of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin dependent diabetics with nephropathy
J Intern Med, 229 (2), 163-70
DOI 10.1111/j.1365-2796.1991.tb00325.x, PubMed 1847721

Publications 1990

Brekke IB, Holdaas H, Albrechtsen D, Fauchald P, Flatmark A (1990)
Combined pancreatic and renal transplantation: improved survival of uremic diabetic patients and renal grafts
Transplant Proc, 22 (4), 1580
PubMed 2389410

Holdaas H, Brekke IB, Hartmann A, Fauchald P, Berg KJ, Sødal G, Jervell J, Flatmark A (1990)
Metabolic control in recipients of duct-occluded segmental pancreatic grafts: a four-year follow-up
Transplant Proc, 22 (2), 655-6
PubMed 2327010

Holdaas H, Hartmann A, Talseth T, Fauchald P, Sødal G, Brekke IB, Berg KJ (1990)
Change in intrarenal sodium reabsorption following donor nephrectomy
Transplant Proc, 22 (1), 246
PubMed 2309323

Norstein J, Brekke IB, Holdaas H, Vatne K (1990)
Arterial stenoses in duct occluded segmental pancreatic grafts treated with percutaneous transluminal angioplasty
Transplant Proc, 22 (2), 599-601
PubMed 2139263

Publications 1989

Holdaas H, Brekke IB, Hartmann A, Talseth T, Sødal G, Jervell J, Flatmark A (1989)
Long-term metabolic control in recipients of duct-occluded segmental pancreatic grafts
Transplant Proc, 21 (1 Pt 3), 2854-5
PubMed 2650384

Tydén G, Brattström C, Bolinder J, Bohman SO, Groth CG, Brekke IB, Holdaas H, Flatmark A (1989)
Long-term metabolic control in recipients of segmental-pancreas grafts with pancreaticoenterostomy or duct obstruction
Diabetes, 38 Suppl 1, 94-6
DOI 10.2337/diab.38.1.s94, PubMed 2642864

Publications 1988

Hartmann A, Holdaas H (1988)
[Emergency treatment of serious hypertension]
Tidsskr Nor Laegeforen, 108 (33), 3108-10
PubMed 3206505

Holdaas H, Hartmann A, Talseth T, Berg KJ, Fauchald P, Stenstrøm J, Djøseland O, Nordal KP, Brodwall E (1988)
Short-term changes in renal function of the remaining kidney after donor nephrectomy
Transplant Proc, 20 (3), 434-5
PubMed 3381255

Holdaas H, Talseth T, Berg KJ, Fauchald P, Nordal KP, Hartmann A (1988)
Diagnostic value of peripheral plasma renin response to a single dose of captopril in suspected renal transplant artery stenosis
Transplant Proc, 20 (3), 423-4
PubMed 3289174

Talseth T, Holdaas H, Albrechtsen D, Berg KJ, Fauchald P, Naalsund A, Nordal KP, Skar AG, Sødal G, Flatmark A (1988)
Increasing incidence of Pneumocystis carinii pneumonia in renal transplant patients
Transplant Proc, 20 (3), 400-1
PubMed 3289169

Publications 1986

Hartmann A, Langberg H, Holdaas H, Kiil F (1986)
Glomerulotubular balance during renal sympathetic stimulation
Acta Physiol Scand, 127 (2), 187-95
DOI 10.1111/j.1748-1716.1986.tb07893.x, PubMed 2873711

Publications 1985

Holdaas H, Kopp UC, DiBona GF (1985)
Modulation of reflex renal vasoconstriction by increased endogenous renal prostaglandin synthesis
J Pharmacol Exp Ther, 232 (3), 725-31
PubMed 3973825

Vikse A, Holdaas H, Sejersted OM, Kiil F (1985)
Haemodynamic conditions for renal PGE2 and renin release during alpha- and beta-adrenergic stimulation in dogs
Acta Physiol Scand, 124 (2), 163-72
DOI 10.1111/j.1748-1716.1985.tb07648.x, PubMed 2861715

Publications 1984

Hartmann A, Holdaas H, Steen PA, Kiil F (1984)
Evidence for bicarbonate-dependent lithium reabsorption in dog kidneys
Acta Physiol Scand, 120 (2), 257-64
DOI 10.1111/j.1748-1716.1984.tb00132.x, PubMed 6231805

Hartmann A, Langberg H, Holdaas H, Kiil F (1984)
Glomerular filtration rate and PCO2 as determinants of lithium reabsorption
Acta Physiol Scand, 121 (3), 283-90
DOI 10.1111/j.1748-1716.1984.tb07458.x, PubMed 6089506

Holdaas H, DiBona GF (1984)
On the existence of renal vasodilator nerves
Proc Soc Exp Biol Med, 176 (4), 426-33
DOI 10.3181/00379727-176-41893, PubMed 6463053

Holdaas H, DiBona GF (1984)
Stimulatory and inhibitory reflexes from somatic receptors: effect on renin release
Am J Physiol, 246 (6 Pt 2), R1005-10
DOI 10.1152/ajpregu.1984.246.6.R1005, PubMed 6377915

Langberg H, Hartmann A, Holdaas H, Kiil F (1984)
Site and magnitude of the tubular inhibitory effect of expanding the extracellular volume in dogs
Acta Physiol Scand, 122 (3), 285-98
DOI 10.1111/j.1748-1716.1984.tb07512.x, PubMed 6516881

Langård O, Holdaas H, Vikse A, Sejersted OM, Eide I (1984)
Ouabain inhibits renin release by a direct renal haemodynamic effect
Scand J Clin Lab Invest, 44 (6), 557-63
DOI 10.1080/00365518409083611, PubMed 6148785

Vikse A, Holdaas H, Sejersted OM, Kiil F (1984)
Relationship between PGE2 and renin release in dog kidneys. Effects of afferent arteriolar dilation and adrenergic stimulation
Acta Physiol Scand, 121 (3), 261-8
DOI 10.1111/j.1748-1716.1984.tb07455.x, PubMed 6382924

Publications 1983

Holdaas H (1983)
Adrenergic control of renin release
J Oslo City Hosp, 33 (10-11), 111-27
PubMed 6315904

Langård O, Holdaas H, Eide I, Kiil F (1983)
Conditions for augmentation of renin release by theophylline
Scand J Clin Lab Invest, 43 (1), 9-14
PubMed 6312554

Osborn JL, Holdaas H, Thames MD, DiBona GF (1983)
Renal adrenoceptor mediation of antinatriuretic and renin secretion responses to low frequency renal nerve stimulation in the dog
Circ Res, 53 (3), 298-305
DOI 10.1161/01.res.53.3.298, PubMed 6349846

Vikse A, Holdaas H, Hartmann A, Kiil F (1983)
Segmental distribution of vascular resistances during ureteral occlusion. The vasoconstrictive effects of angiotensin and CaCl2 differ from those of catecholamines and renal nerve stimulation
Acta Physiol Scand, 119 (2), 147-58
DOI 10.1111/j.1748-1716.1983.tb07320.x, PubMed 6140816

Vikse A, Holdaas H, Sejersted OM, Eide I, Kiil F (1983)
Prostaglandin E2 and renin release response to dilation of afferent arterioles and during alpha- and beta-adrenergic stimulation
Acta Med Scand Suppl, 677, 44-7
DOI 10.1111/j.0954-6820.1984.tb08627.x, PubMed 6322531

Publications 1982

Holdaas H, Langaard O, Eide I, Kiil F (1982)
Conditions for enhancement of renin release by isoproterenol, dopamine, and glucagon
Am J Physiol, 242 (3), F267-73
DOI 10.1152/ajprenal.1982.242.3.F267, PubMed 7039349

Publications 1981

Holdaas H, DiBona GF, Kiil F (1981)
Effect of low-level renal nerve stimulation on renin release from nonfiltering kidneys
Am J Physiol, 241 (2), F156-61
DOI 10.1152/ajprenal.1981.241.2.F156, PubMed 7023249

Holdaas H, Langård O, Eide I, Kiil F (1981)
Mechanism of renin release during renal nerve stimulation in dogs
Scand J Clin Lab Invest, 41 (7), 617-25
DOI 10.3109/00365518109090506, PubMed 7041238

Langberg H, Mathisen O, Holdaas H, Kiil F (1981)
Filtered bicarbonate and plasma pH as determinants of renal bicarbonate reabsorption
Kidney Int, 20 (6), 780-8
DOI 10.1038/ki.1981.211, PubMed 6801371

Langård O, Holdaas H, Eide I, Kiil F (1981)
Conditions for humoral alpha-adrenoceptor stimulation of renin release in anaesthetized dogs
Scand J Clin Lab Invest, 41 (6), 527-34
DOI 10.3109/00365518109090494, PubMed 6278576

Langård O, Holdaas H, Eide I, Kiil F (1981)
Conditions for stimulation of renin release by cyclic AMP in anaesthetized dogs
Scand J Clin Lab Invest, 41 (6), 535-42
DOI 10.3109/00365518109090495, PubMed 6278577

Publications 1979

Mathisen O, Holdaas H, Kiil F (1979)
Re-examination of the dose-reponse relationship for the renal effect of acetozolamide
Scand J Clin Lab Invest, 39 (4), 297-301
DOI 10.3109/00365517909106112, PubMed 523981

Mathisen O, Monclair T, Holdaas H, Kiil F (1979)
To what extent does acetazolamide inhibit renal bicarbonate reabsorption?
Scand J Clin Lab Invest, 39 (4), 293-5
DOI 10.3109/00365517909106111, PubMed 118512

Publications 1978

Mathisen O, Monclair T, Holdaas H, Kiil F (1978)
Bicarbonate as mediator of proximal tubular NaCl reabsorption and glomerulotubular balance
Scand J Clin Lab Invest, 38 (1), 7-17
DOI 10.3109/00365517809108396, PubMed 415348

Sejersted OM, Holdaas H, Monclair T (1978)
Functional differences of ouabain and ethacrynic acid on renal potassium metabolism in dogs
Scand J Clin Lab Invest, 38 (7), 603-14
DOI 10.3109/00365517809102426, PubMed 152453

Page visits: 6976